Skip to content

Evaluation of Deposits on Contact Lenses Worn Extended Wear

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00725530
Enrollment
54
Registered
2008-07-30
Start date
2008-03-31
Completion date
2008-10-31
Last updated
2012-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Lens deposits, Soft contact lens wearers

Brief summary

The purpose of this study was to measure lipid deposits on commercially marketed contact lenses when worn on an extended wear (overnight) basis for 7 days.

Interventions

Commercially marketed, silicone hydrogel contact lens

DEVICEetafilcon A contact lens (Acuvue2)

Commercially marketed, hydrogel contact lens

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 or older. * Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with contact lenses. * Successfully wearing hydrogel or silicone hydrogel contact lenses. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Evidence or history of ocular conditions as prescribed in the protocol. * One functional eye or a monofit lens. * Any slit-lamp finding score of (1) at the Screening Visit as defined by the protocol. * Use of concomitant topical ocular prescription or over-the-counter ocular medications. * History of seasonal allergies with significant ocular side effects. * Other protocol-defined

Design outcomes

Primary

MeasureTime frameDescription
Front Surface Lens Deposits7 daysFilm and discrete deposits were assessed with a slit-lamp after 2-5 hours of open eye lens wear. Film deposits were recorded on a 5-point scale, where 0=no deposition, clean surface; 1=slight, deposition occupying 1-5% of lens front surface; 2=mild, deposition occupying 6-15% of lens front surface; 3=moderate, deposition occupying 16-25% of lens front surface; 4=severe, deposition occupying \>25% of lens front surface. Discrete deposits were recorded on a 5-point scale, where 0=no deposition, clean surface; 1=microdeposits (less than or equal to 10 dots); 2=microdeposits (greater than 10 dots); 3=macro deposits; 4=one or more jelly bumps. Participants were classified into Front Surface Lens Deposits \<2 (less than grade 2 for both film and discrete) and into front surface lens deposits \>1 (greater than grade 1 for either film, discrete, or both).

Countries

United States

Participant flow

Recruitment details

Each site enrolled normal participants (non-depositors) and depositors in approximately a 1:1 ratio, as outlined in the protocol. 54 participants in 3 US sites and 1 UK site were enrolled.

Pre-assignment details

Participants meeting eligibility criteria at the screening visit were enrolled into the study. 48 hours of no lens wear prior to Visit 1 served as the washout period. This reporting group includes all enrolled and dispensed participants.

Participants by arm

ArmCount
Overall
This reporting group includes all enrolled and dispensed participants.
54
Total54

Baseline characteristics

CharacteristicOverall
Age Continuous32.35 years
STANDARD_DEVIATION 12.71
Sex: Female, Male
Female
42 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 540 / 54
serious
Total, serious adverse events
0 / 540 / 54

Outcome results

Primary

Front Surface Lens Deposits

Film and discrete deposits were assessed with a slit-lamp after 2-5 hours of open eye lens wear. Film deposits were recorded on a 5-point scale, where 0=no deposition, clean surface; 1=slight, deposition occupying 1-5% of lens front surface; 2=mild, deposition occupying 6-15% of lens front surface; 3=moderate, deposition occupying 16-25% of lens front surface; 4=severe, deposition occupying \>25% of lens front surface. Discrete deposits were recorded on a 5-point scale, where 0=no deposition, clean surface; 1=microdeposits (less than or equal to 10 dots); 2=microdeposits (greater than 10 dots); 3=macro deposits; 4=one or more jelly bumps. Participants were classified into Front Surface Lens Deposits \<2 (less than grade 2 for both film and discrete) and into front surface lens deposits \>1 (greater than grade 1 for either film, discrete, or both).

Time frame: 7 days

Population: All enrolled participants.

ArmMeasureGroupValue (NUMBER)
Balafilcon AFront Surface Lens DepositsDeposits graded <220 Participants
Balafilcon AFront Surface Lens DepositsDeposits graded >134 Participants
Etafilcon AFront Surface Lens DepositsDeposits graded <225 Participants
Etafilcon AFront Surface Lens DepositsDeposits graded >129 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026